Versican G3-expressing breast cancer cells demonstrated enhanced cell survival in serum free medium and chemotherapy by activating EGFR/ERK signaling and its down-stream pathway proteins CDK2 and GSK-3β (S9P). This evidence concerns the gene MAPK1 and breast carcinoma.